Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new strategic partnership between Fiocruz and The Global Health Network will amplify the impact of Fiocruz’s health research and capacity development initiatives by promoting research capacity building across Portuguese-speaking countries, and enabling research findings from the Zika outbreak to benefit public health worldwide.

Composite photo of the Signing of the agreement between The Global Health Network and Fiocruz - plus a group photo

Fiocruz, one of the world’s leading public health institutions and Brazil’s institute for health science and technology, has signed an agreement with The Global Health Network at the University of Oxford to enable evidence generated from research to drive improvements in global health in the most resource-poor and hard to reach areas of the globe.

This new partnership will:

  • Establish a knowledge sharing hub for Fiocruz, embedded within The Global Health Network. This hub will enhance the visibility of Fiocruz’s research and capacity development activities on this global platform. It will both connect existing partners and promote new partnerships, inviting the rest of the world to learn from and benefit from their advances. 
  • Promote research capacity building across Portuguese-speaking countries. With an initial focus on Angola, followed by Mozambique, Fiocruz and The Global Health Network will collaborate with local research organisations to promote access to training, support, tools and resources for local health works – all in Portuguese. This aims to overcome language as a barrier to conducting research, giving health workers the skills and training to build their career through research experience.
  • Share research findings and recommendations from the Zika outbreak. A knowledge sharing hub will consolidate and communicate findings from the three Zika research consortia to health workers, research teams and, most importantly, the families impacted by this devastating outbreak. It will provide a powerful mechanism for sharing the findings and helping these results get back to the community, local health delivery teams and into practice to make a lasting impact. Through sharing recommendations arising from research during the outbreak, the results can be used for public health benefit and, over time, become an integral part of vector control activities. This is an important outcome for ZikaPLAN and ZIKAction*, and for ZIKAlliance an opportunity to contribute by sharing information that can be useful for feeding the platform.

Fiocruz has a long history of embedding health research into health systems and building research capacity through equipping health workers with the skills to put research results into practice and generate evidence, with outcomes that improve the lives of their communities. The Global Health Network brings its extensive experience in knowledge sharing and communities of practice to amplify the impact of Fiocruz’s work on a global scale.

A shared ethos between Fiocruz and The Global Health Network underpins this partnership: firstly, that public health can be improved through research and, secondly, in which the advances from each programme enriches the others. By building capacity for research across the globe, evidence can be generated where such data is missing, across diseases, geographies and communities, and the impacts of this research can be accelerated when methods, best practice and experience are shared.

About The Global Health Network

More, better and faster research is critical to solving the world’s biggest health challenges. The Global Health Network is sharing knowledge, methods and tools between disease areas, regions and organisations to amplify evidence generation. Research teams and professionals are being trained and supported to lead and undertake health research in the world’s most challenging settings. This is achieved by applying the best digital technology and harnessing the sharing phenomena, working virtually and on the ground to enable the capture of life-saving data.

About Fiocruz

Fiocruz is the most prominent Institution of Science and Technology in Health in Latin America, whose mission is to produce, disseminate and share knowledge and technologies, aiming at strengthening and consolidating the Unified Health System and the promotion of health and quality of life for the population

Funding

Eu flag *This project has received funding from the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement No.s 734584, 734857.

Similar stories

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Indian authorities sign an MoU for a data and skill-sharing partnership between ICMR and IDDO

The Indian government’s Union Cabinet, chaired by Prime Minister Shri Narendra Modi, has approved a Memorandum of Understanding (MoU) between the Indian Council of Medical Research (ICMR) and the Infectious Diseases Data Observatory (IDDO), based at the University of Oxford.

The GRAM Project has moved

The Global Research on Antimicrobial Resistance (GRAM) Project has a new centre of operations at the University of Oxford, after moving this month from the Big Data Institute to the Centre for Tropical Medicine and Global Health, under the leadership of Dr. Benn Sartorius (PI) and Prof. Christiane Dolecek (co-PI).

Sharing expertise with scientific collaborators in India

The Indian Council for Medical Research (ICMR) National Institute of Malaria Research (NIMR) and IDDO collaborate on a joint capacity building venture to train young researchers across three infectious diseases: malaria, visceral leishmaniasis and lymphatic filariasis

Artemisinin combination therapy trials need longer follow-up to detect late treatment failures for Plasmodium falciparum malaria

WWARN researchers have been assessing the recommended minimum follow-up period in capturing polymerase chain reaction (PCR)-confirmed recrudescence following treatment with fixed-dose artemisinin combination therapies (ACTs) for patients with uncomplicated Plasmodium falciparum malaria.

Paxlovid to be investigated by the RECOVERY Trial as a potential treatment for patients hospitalised with COVID-19

The RECOVERY Trial begins testing the antiviral treatment Paxlovid. Paxlovid, an oral antiviral treatment developed by Pfizer, is a combination of nirmatrelvir and ritonavir. Nirmatrelvir inhibits an enzyme that is critical for the replication of the virus that causes COVID-19, whilst ritonavir increases the concentration of nirmatrelvir.